{"product_id":"cgen-pestle-analysis","title":"(CGEN) Compugen Ltd. PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Compugen Ltd. PESTLE Analysis shows how political, economic, social, technological, legal, and environmental forces affect the company; the page includes a real preview sample so you can assess style and depth. It’s useful for strategy, investment, or research—purchase the full report to access the complete, ready-to-use company-specific analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIsrael, United States, Europe footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompugen Ltd. spans Israel, the United States, and Europe, so its trials and partner deals depend on three regulatory regimes and steady cross-border approvals. The EU GDPR can fine data breaches up to 4% of global annual revenue, which makes data transfer and site-level continuity a real risk. Any geopolitical shock in one region can slow trial timing, logistics, and partner coordination.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e1993 Israel-based headquarters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompugen Ltd’s Holon, Israel base ties it to a country that spends about 6% of GDP on R\u0026amp;D, one of the highest rates in the OECD, so national life-science support can help fund discovery work.\u003c\/p\u003e\n\u003cp\u003eIsraeli grants and tax support for export-led biotech can lower development costs and speed partnerships.\u003c\/p\u003e\n\u003cp\u003eStill, regional security risk can disrupt staffing, logistics, and investor sentiment fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical-stage immuno-oncology pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompugen Ltd’s Phase I and Phase I\/II immuno-oncology programs rely on fast health-authority feedback, so even small rule changes can delay patient enrollment and readouts. Political shifts in national research policy, ethics review, and approval timelines can slow cross-border trials and raise costs. When governments push oncology innovation, public grants and partner deals become easier to win, which matters a lot for a clinical-stage company with no approved products yet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eStrategic alliances with Bayer, BMS, AstraZeneca\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompugen Ltd. uses 3 major alliances with Bayer, BMS, and AstraZeneca to share R\u0026amp;D cost and lower standalone development risk, while also widening access to global markets. The trade-off is policy and regulatory dependence: each partner follows its own national priorities, so milestone timing and deal terms can shift fast. Any change in cross-border pharma rules can hit payment cadence and commercial plans.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 global partners reduce solo risk\u003c\/li\u003e\n\u003cli\u003eDifferent regulators can slow milestones\u003c\/li\u003e\n\u003cli\u003ePolicy shifts can alter deal timing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUniversity links with Johns Hopkins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompugen Ltd.'s work with Johns Hopkins can speed early T cell and myeloid checkpoint validation, because Johns Hopkins runs about $3.2 billion in annual research spending and has deep translational talent. But these ties depend on public grant flows, ethics review, and university governance, so political support for NIH-style funding can change the pace of Compugen Ltd.'s preclinical pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore public funding can widen discovery work.\u003c\/li\u003e\n\u003cli\u003eGrant cuts can slow validation and timelines.\u003c\/li\u003e\n\u003cli\u003eGovernance rules can shape data sharing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompugen Faces Geopolitics, GDPR, and Trial Timing Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompugen Ltd. is exposed to Israel, the United States, and Europe, so trial timing, approvals, and data rules can shift with politics. Israel spends about 6% of GDP on R\u0026amp;D, which supports biotech, but security risk can still disrupt staff and logistics. EU GDPR fines can reach 4% of global revenue, so cross-border data handling stays a key risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIsrael R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e~6% GDP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGDPR fine\u003c\/td\u003e\n\u003ctd\u003eUp to 4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartners\u003c\/td\u003e\n\u003ctd\u003eBayer, BMS, AstraZeneca\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eMaps how Political, Economic, Social, Technological, Environmental, and Legal forces shape Compugen Ltd.’s strategy, risks, and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise Compugen Ltd. PESTLE snapshot that quickly clarifies external risks and opportunities for faster planning and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary, reputable sources backing market sizing, pricing, and competitive assumptions to speed due diligence and verify claims quickly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase I and Phase I\/II funding intensity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhase I and Phase I\/II work is cash-heavy and usually brings no product revenue, so Compugen must pay for trials, GMP manufacturing, and R\u0026amp;D before any launch. In 2025, access to equity, debt, or partner cash was still central for biotech; Compugen's ability to keep a multiyear runway depends on that funding. If capital markets tighten, trial pace and data readouts can slow fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti-program oncology pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompugen Ltd. is advancing four main oncology shots on goal: COM701, COM902, Bapotulimab, and AZD2936, plus earlier-stage programs. That spread can reduce single-asset risk, but it also keeps annual R\u0026amp;D spend high as each trial needs capital.\u003c\/p\u003e\n\u003cp\u003eThe pipeline’s economic value still hinges on the next clinical readouts, since one positive study can re-rate the whole platform. Deal economics also matter: upfront cash, milestones, and royalties can change the value far more than the science alone.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma partner economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompugen Ltd. benefits from 3 major pharma partners, Bayer, Bristol-Myers Squibb, and AstraZeneca, which can bring milestone cash, shared R\u0026amp;D spend, and future royalties. That setup usually cuts cash burn versus fully self-funded drug work, but the upside depends on trial wins and each partner’s portfolio focus. Partner economics can shift fast if a program slips, gets deprioritized, or is renegotiated.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGlobal biotech capital markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompugen Ltd. sits in a market where biotech funding is still selective: the Nasdaq Biotech Index rose about 4% in 2025, but 10-year U.S. yields stayed near 4% to 4.5%, keeping capital costly for clinical-stage names. Investor appetite stays tied to oncology and immunotherapy data, so strong readouts can move valuation fast and reopen financing options.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher rates lift dilution risk\u003c\/li\u003e\n\u003cli\u003eRisk-on flows favor cancer assets\u003c\/li\u003e\n\u003cli\u003ePositive data can reset valuation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUS and Europe commercialization potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompugen Ltd.'s revenue upside is tied to the U.S. and Europe, where cancer demand is huge: the American Cancer Society projected 2.0 million new U.S. cancer cases in 2024, and Europe recorded about 4.7 million new cases in 2022. These markets can support premium antibody pricing, but payers require strong comparative data and clear health-economic proof before broad reimbursement.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge oncology patient pools\u003c\/li\u003e\n\u003cli\u003eHigh launch-price potential\u003c\/li\u003e\n\u003cli\u003eStrict reimbursement review\u003c\/li\u003e\n\u003cli\u003eApproval can drive step-change revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompugen’s Fate Hinges on Funding, Milestones, and Biotech Sentiment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompugen Ltd.’s economics still hinge on pricey 2025-2026 biotech capital: phase I\/II trials burn cash before revenue, so funding and partner milestones matter most. Higher rates near 4%-4.5% keep dilution risk elevated, while a roughly 4% rise in the Nasdaq Biotech Index in 2025 shows selective risk appetite. Oncology demand stays large, with 2.0 million U.S. cases projected for 2024 and 4.7 million European cases in 2022.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFunding cost\u003c\/td\u003e\n\u003ctd\u003e4%-4.5% yields\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech sentiment\u003c\/td\u003e\n\u003ctd\u003e+4% NBI in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket size\u003c\/td\u003e\n\u003ctd\u003e2.0m \/ 4.7m cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eCompugen Ltd. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Compugen Ltd. PESTLE Analysis you’ll receive after purchase—fully formatted and ready to use. This file is the final version, professionally structured with no placeholders or teasers. The content, layout, and analysis visible here are exactly what you’ll download instantly after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh unmet need in advanced cancer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWHO estimated 20.0 million new cancer cases and 9.7 million deaths in 2022, and many patients with advanced solid tumors still need options beyond checkpoint inhibitors. That keeps unmet need high in Compugen Ltd.'s core markets of solid tumors and advanced malignancies. As a result, its immuno-oncology pipeline has a clear social value case, especially where current standards still leave many patients without durable benefit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision medicine and biomarker expectations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOncology stakeholders now expect targeted therapies with clear patient-selection logic, and the FDA has cleared more than 80 biomarker-linked cancer drugs, showing how normal this model has become. Compugen Ltd.’s checkpoint and bispecific programs fit that shift toward mechanism-based treatment. If clinical data stay strong, social acceptance of personalized cancer care can speed uptake and payer support.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient safety and tolerability focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompugen Ltd.’s Bristol-Myers Squibb collaboration centers on safety and tolerability for COM701 with Opdivo, which matters because oncology trust rises or falls on toxicity control and benefit-risk balance. Cancer remains a major social issue, with 20 million new cases worldwide in 2022, so patients and clinicians are highly sensitive to adverse events. A cleaner safety profile can lift clinician confidence and improve trial enrollment willingness.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGlobal trial recruitment needs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompugen Ltd’s solid-tumor trials need broad, diverse enrollment, and slow recruitment can push back readouts and raise spend; oncology studies often need hundreds of patients, so awareness, physician referrals, and patient trust directly shape timelines. In 2025, Compugen held $46.0 million in cash and equivalents, so trial delays can matter fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroader awareness lifts enrollment\u003c\/li\u003e\n\u003cli\u003ePhysician referrals drive trial starts\u003c\/li\u003e\n\u003cli\u003eSlow screening delays data\u003c\/li\u003e\n\u003cli\u003eLonger trials increase cash burn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eScientific reputation and academic validation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompugen Ltd.'s collaboration with Johns Hopkins adds scientific credibility in immune checkpoint and myeloid research, and that kind of academic validation matters in biotech. Social proof from a top-tier institution can lift investor confidence, strengthen key opinion leader support, and make it easier to recruit researchers and trial sites.\u003c\/p\u003e\n\u003cp\u003eThis is especially important when programs are early-stage and need external trust fast. In practice, a respected partner can shorten the time needed to build trial momentum and can improve deal and funding conversations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eJohns Hopkins link boosts scientific trust.\u003c\/li\u003e\n\u003cli\u003eHelps win KOL and investor backing.\u003c\/li\u003e\n\u003cli\u003eCan improve researcher and site recruitment.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompugen Sees Strong Demand as Global Cancer Burden Stays High\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSociological demand for Compugen Ltd. stays high because cancer burden remains huge: WHO counted 20.0 million new cases and 9.7 million deaths in 2022. Patient and clinician interest is strongest where checkpoint inhibitors still fail, so biomarker-led trials and cleaner safety profiles can support trust, enrollment, and uptake.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2022 global cancer cases\u003c\/td\u003e\n\u003ctd\u003e20.0 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2022 cancer deaths\u003c\/td\u003e\n\u003ctd\u003e9.7 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompugen Ltd. cash and equivalents (2025)\u003c\/td\u003e\n\u003ctd\u003e$46.0 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e4 named antibody programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompugen Ltd. has 4 named antibody programs: COM701, COM902, Bapotulimab, and AZD2936. The mix covers monotherapy, combination therapy, and bispecific design, so the tech stack is built around immune checkpoint modulation.\u003c\/p\u003e\n\u003cp\u003eThis approach gives Compugen multiple shots on target in a field where checkpoint inhibitors already drive multibillion-dollar oncology sales.\u003c\/p\u003e\n\u003cp\u003eAZD2936 also shows platform validation through AstraZeneca, while the other programs keep the pipeline diversified across CD112R, TIGIT, and PVRIG biology.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBispecific antibody platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompugen Ltd.'s bispecific antibody platform is a key tech edge, with AZD2936 combining TIGIT and PD-1 in one molecule to raise target precision. Bispecifics can improve binding control, but they are harder to design and scale than single antibodies; industry data show many programs still fail in CMC (chemistry, manufacturing, and controls) or affinity tuning. Technical value depends on stable expression, clean manufacturability, and reproducible yield.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyeloid target emphasis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompugen Ltd. is pushing earlier-stage myeloid programs, so its tech base is broader than T cell checkpoint work. That matters because myeloid biology can open new drug targets in immuno-oncology. It may also help Compugen stand out in a crowded field where many peers still chase the same checkpoint pathways.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePhase I clinical development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompugen Ltd.’s core programs are still in Phase I, so translational science is the main tech risk: only about 1 in 10 oncology drugs entering Phase I reaches approval. Preclinical hits must convert into human safety and efficacy, and weak assay design can blur the signal fast. Biomarker and data quality choices now shape later go\/no-go calls, which is critical in small cohorts of usually under 100 patients.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase I = highest translation risk\u003c\/li\u003e\n\u003cli\u003eBiomarkers must prove human signal\u003c\/li\u003e\n\u003cli\u003eAssay quality drives decision accuracy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCross-company combination studies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompugen Ltd. tests COM701 with Opdivo and uses big-partner pathways to move from early signals to later studies. Combination work only scales if the molecules, dose timing, and clinical end points line up, so compatibility is a real tech gate, not a side issue.\u003c\/p\u003e\n\u003cp\u003eStrong translational tools are the key: they need to show synergy in tumor biology and patient response before more capital goes into larger trials. In plain terms, if the combo cannot prove added benefit fast, later-stage investment gets harder to justify.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCOM701 plus Opdivo needs tight protocol fit.\u003c\/li\u003e\n\u003cli\u003eDose, timing, and endpoints must match.\u003c\/li\u003e\n\u003cli\u003eBiomarkers must show real synergy early.\u003c\/li\u003e\n\u003cli\u003ePartner data can unlock bigger trials.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompugen’s 4-Program Antibody Platform Faces a Big Phase I Test\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompugen Ltd.'s tech edge is its 4-program antibody platform, led by COM701, COM902, Bapotulimab, and AZD2936. The main risk is translation: only about 10% of oncology drugs entering Phase I reach approval, so biomarker quality, dose fit, and assay control matter fast. AZD2936 also validates the platform through AstraZeneca, while bispecific design raises CMC complexity.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNamed programs\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase I oncology success rate\u003c\/td\u003e\n\u003ctd\u003e~10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial regulation in 3 regions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompugen Ltd. must clear three trial regimes: Israel, the United States, and the EU\/EEA. The EU Clinical Trials Regulation now runs through CTIS across 30 countries, while US trials face FDA, IRB, and IND rules. Each market has its own ethics, approval, and safety-reporting steps, so delays can slow study starts and push timelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma partnership contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompugen Ltd.’s pharma partnerships with Bayer, BMS, AstraZeneca, and Johns Hopkins create 4 binding agreements that set IP ownership, data-use rights, milestones, and termination terms. These clauses shape who controls assets and when cash can be earned, so legal precision drives value. In biotech, even one weak clause can delay payments or weaken royalty rights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual property protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompugen Ltd.’s antibody candidates and target discoveries depend on patents and trade-secret protection, because patent terms generally run 20 years from filing. In biotech, weak or challenged IP can erase value fast, so patent strength and geographic coverage matter as much as the science. That makes claim scope, filing timing, and major-market coverage core legal assets for 2025-2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDrug safety and disclosure duties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical-stage biotechs like Compugen Ltd. must disclose material trial data, serious adverse events, and key development risks fast. In the U.S., many material events must be filed on Form 8-K within 4 business days, and any disputed safety disclosure can trigger SEC or investor claims. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eMaterial trial results need prompt disclosure\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eSerious adverse events raise legal risk\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003e8-K timing supports market transparency\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eDisclosure disputes can drive litigation\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLicensing agreement with AstraZeneca\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompugen Ltd.’s licensing agreement with AstraZeneca ties bi-specific and multi-specific immuno-oncology antibodies to strict legal rights on scope, field-of-use, and commercialization. That means any breach, delay, or ownership dispute can limit freedom to operate and weaken future monetization from the program.\u003c\/p\u003e\n\u003cp\u003eThe key legal risk is not just contract compliance but who controls next-step development and any milestone-triggered payments. If the parties disagree on exclusivity or use rights, strategy can shift fast and Compugen Ltd. may lose value even if the science stays strong.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eControls scope and use rights.\u003c\/li\u003e\n\u003cli\u003eCan block future monetization.\u003c\/li\u003e\n\u003cli\u003eMilestone disputes may alter strategy.\u003c\/li\u003e\n\u003cli\u003eFreedom to operate is critical.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompugen Faces Tight EU, FDA, SEC, and Patent Legal Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompugen Ltd. faces legal risk from 30-country EU CTIS trial rules, U.S. FDA\/IRB\/IND oversight, and fast SEC disclosure duties, including many material events on Form 8-K within 4 business days. Its 4 major partnerships also lock in IP, field-of-use, and milestone rights. Patent protection matters too, since terms usually run 20 years from filing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal factor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU trials\u003c\/td\u003e\n\u003ctd\u003e30 countries via CTIS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS disclosure\u003c\/td\u003e\n\u003ctd\u003e8-K in 4 business days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent term\u003c\/td\u003e\n\u003ctd\u003e20 years from filing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore deals\u003c\/td\u003e\n\u003ctd\u003e4 major partnerships\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLab and clinical supply footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompugen’s lab work and clinical trials rely on energy-heavy sites, single-use plastics, and cold-chain shipping; the health sector is estimated to drive 4.4% of global net emissions. Efficient vendor control matters because packaging and transport can quickly raise cost and carbon. Strong, compliant supply management helps keep trials running and reduces waste and stockouts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiologics manufacturing inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompugen Ltd. relies on specialized biologic inputs and a 2-8°C cold chain, so even short temperature drifts can damage antibody materials and delay releases. Waste handling and tight inventory control matter because biologics are resource intensive, and U.S. FDA data show 1 in 5 drug shortages in 2025 were linked to manufacturing or supply issues. Storms, port delays, or power cuts can still disrupt delivery timing and reduce material stability. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eESG expectations from global partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge pharma partners now screen suppliers on ESG, and EU CSRD will push about 50,000 companies into deeper environmental disclosure. For Compugen Ltd, clear Scope 1-3 reporting can lift partner confidence and support alliance renewals. Environmental data is no longer optional in vendor reviews; it is part of contract risk checks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEnergy and facilities usage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompugen Ltd.'s clinical research and molecular biology work still depends on electricity, HVAC, and lab consumables, even without heavy manufacturing. Lab space can use 3 to 10 times more energy than standard office space, so heating, cooling, and ventilation directly affect costs and emissions.\u003c\/p\u003e\n\u003cp\u003eIn FY2025, that makes facility efficiency a real operating lever, not just an ESG item. Lower-resource labs also reduce supply strain and outage risk, which can support resilience and strengthen the Company Name's reputation with partners and investors.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh HVAC use drives lab emissions\u003c\/li\u003e\n\u003cli\u003eEfficient space lowers operating cost\u003c\/li\u003e\n\u003cli\u003eLean facilities improve resilience\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eResilience to external disruptions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eWeather, transport delays, and local outages can slow Compugen Ltd trial kits, samples, and data flow across sites. With work spread across multiple geographies, the company needs backup couriers, cold-chain checks, and site-level contingency plans to keep studies on track. That resilience matters for both GCP compliance and trial speed, because even short disruptions can push timelines and raise operating costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProtect sample integrity.\u003c\/li\u003e\n\u003cli\u003eUse alternate transport routes.\u003c\/li\u003e\n\u003cli\u003eBuild site backup plans.\u003c\/li\u003e\n\u003cli\u003eKeep trials compliant and moving.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompugen’s Key ESG Risks: Lab Energy, Cold Chain, and Waste\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompugen Ltd.’s main environmental risks are energy-heavy labs, cold-chain logistics, and waste from single-use materials. Lab space can use 3–10x more energy than offices, and health care drives 4.4% of global net emissions. Strong Scope 1-3 tracking and backup transport help cut cost and disruption.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab energy\u003c\/td\u003e\n\u003ctd\u003e3-10x office use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealth sector\u003c\/td\u003e\n\u003ctd\u003e4.4% emissions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrug shortages\u003c\/td\u003e\n\u003ctd\u003e20% supply-linked\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234211242249,"sku":"cgen-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/cgen-pestle-analysis.webp?v=1785714716","url":"https:\/\/dcfanalyst.com\/products\/cgen-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}